Revelation Biosciences Statistics
Share Statistics
Revelation Biosciences has 6.46M shares outstanding. The number of shares has increased by -40.32% in one year.
| Shares Outstanding | 6.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 130.14% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.35M |
| Failed to Deliver (FTD) Shares | 11.52K |
| FTD / Avg. Volume | 1.14% |
Short Selling Information
The latest short interest is 41.24K, so 0.96% of the outstanding shares have been sold short.
| Short Interest | 41.24K |
| Short % of Shares Out | 0.96% |
| Short % of Float | 0.96% |
| Short Ratio (days to cover) | 0.69 |
Valuation Ratios
The PE ratio is -28.48 and the forward PE ratio is -0.42.
| PE Ratio | -28.48 |
| Forward PE | -0.42 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.52 |
| P/FCF Ratio | -0.47 |
| PEG Ratio | n/a |
Enterprise Valuation
Revelation Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.18, with a Debt / Equity ratio of 0.
| Current Ratio | 2.18 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.02% and return on capital (ROIC) is -130.22%.
| Return on Equity (ROE) | -0.02% |
| Return on Assets (ROA) | -0.01% |
| Return on Capital (ROIC) | -130.22% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -13.36K |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -97.82% in the last 52 weeks. The beta is 0.15, so Revelation Biosciences 's price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | -97.82% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 27.56 |
| Average Volume (20 Days) | 1.01M |
Income Statement
In the last 12 months, Revelation Biosciences had revenue of $0 and earned -$120.25K in profits. Earnings per share was $-0.53.
| Revenue | 0 |
| Gross Profit | -25.05K |
| Operating Income | -8.66M |
| Net Income | -120.25K |
| EBITDA | -95.21K |
| EBIT | - |
| Earnings Per Share (EPS) | -0.53 |
Balance Sheet
The company has $11.99M in cash and $0 in debt, giving a net cash position of $11.99M.
| Cash & Cash Equivalents | 11.99M |
| Total Debt | 0 |
| Net Cash | 11.99M |
| Retained Earnings | -25.47M |
| Total Assets | 6.74M |
| Working Capital | 2.59M |
Cash Flow
In the last 12 months, operating cash flow was -$7.29M and capital expenditures -$4, giving a free cash flow of -$7.29M.
| Operating Cash Flow | -7.29M |
| Capital Expenditures | -4 |
| Free Cash Flow | -7.29M |
| FCF Per Share | -31.96 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
REVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -147.22% |
| FCF Yield | -313.1% |
Analyst Forecast
Currently there are no analyst rating for REVB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 25, 2024. It was a backward split with a ratio of 1:30.
| Last Split Date | Jan 25, 2024 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -11.38 |
| Piotroski F-Score | 1 |